2014-02-05
Myriad Genetics Inc. will buy South San Francisco's Crescendo Bioscience Inc. for $270 million cash, the companies said Tuesday.
The deal positions 130-employee Crescendo — the developer of Vectra DA, a test to help rheumatoid arthritis patients track their disease and their treatment — as a wholly owned subsidiary of Salt Lake City-based Myriad (NASDAQ: MYGN). It also translates into an exit for longtime Crescendo venture backers Mohr Davidow Ventures, Kleiner Perkins Caufield & Byers, Aeris…